eTheRNA Announces Research Agreement with Merck to access mRNA technologies
eTheRNA immunotherapies NV (“eTheRNA”) is pleased to announce the start of a strategic partnership with Merck with the signing of a Research Agreement. The partnership will investigate the application of eTheRNA’s proprietary mRNA design expertise and LNP-delivery platforms to disease areas selected by Merck. The ongoing pandemic has underlined the capability for mRNA vaccines as […]